Inhibition of p38 either with a pharmacological inhibitor or by a genetic approach has been exploited for AA and MDS treatment because p38 inhibition can inhibit hematopoietic stem cell (HSC) apoptosis and stimulate hematopoietic progenitor cell (HPC) proliferation [10], [11]. This evidence concerns the gene MAPK14 and myelodysplastic syndrome.